Following unprecedented results from the RASolute 302 trial, cancer centers across the US are making daraxonrasib available to patients ahead of FDA approval. The RAS inhibitor has been in the news … [+4262 chars]
No comments yet. Be the first to comment!
Your trusted source for breaking news, in-depth analysis, and comprehensive coverage of today's most important stories.
Get daily updates on breaking news, exclusive interviews, and special features delivered to your inbox.
Have a news tip or want to get in touch with our editorial team? We're here to help.
Plot C3-C Jaypee Wishtown Sector 129 Noida Uttar Pradesh 201304 India